In the validation set, 90 astrocytoma samples and 40 NAT samples were also clearly separated into two main classes, with 3 astrocytoma samples and 5 NAT samples incorrectly classified (Fig 1B). The gene discussed is BRD2; the disease is astrocytoma (excluding glioblastoma).